BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (Nasdaq: SGEN - News) today announced that Chris Boerner, Ph.D. has been promoted to Senior Vice President, Commercial. Dr. Boerner joined Seattle Genetics in November 2010 as Vice President, Marketing, and has served as a key member of the commercial organization involved in the launch of ADCETRIS™ (brentuximab vedotin). He replaces Bruce Seeley, former Executive Vice President, Commercial, who is leaving Seattle Genetics to pursue other opportunities.

“Chris has been a strategic leader in our commercial organization for more than a year, and has contributed significantly to the successful launch of ADCETRIS,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “He has brought to Seattle Genetics extensive experience from the commercialization and life-cycle management of several oncology products. We anticipate a seamless transition as we continue to execute on our commercial priorities to bring ADCETRIS to relapsed Hodgkin lymphoma and systemic ALCL patients in need.”

“Bruce has built a strong sales, marketing and reimbursement team that is executing extremely well on the commercialization of ADCETRIS,” added Dr. Siegall. “We thank him for his contributions in preparing the company for its transition to a commercial organization and his leadership through the early launch phase. We wish him the best in his future endeavors.”

Prior to Seattle Genetics, Chris Boerner spent more than eight years at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin and Director of Avastin franchise management. Additionally, he served in a variety of commercial roles across multiple disease areas, including solid tumor oncology, lymphoma and immunology. Dr. Boerner joined Genentech from McKinsey & Company, a global strategic management consulting firm, where he worked on a variety of pharmaceutical sales and marketing engagements. Prior to joining Seattle Genetics in 2010, he most recently led the marketing team at Dendreon. Dr. Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in Economics and History from Washington University in St. Louis.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at http://www.seattlegenetics.com.

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company’s expectations for continued commercial success of ADCETRIS. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, among others, that adverse events for ADCETRIS adversely affect the ability to successfully market ADCETRIS or that planned and future clinical trials do not support additional approvals in earlier lines of therapy or other malignancies. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company’s Form 10-Q for the quarter ended September 30, 2011 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Continue reading here:
Seattle Genetics Provides Update on Commercial Leadership

Comments are closed.